Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: An open-label, randomized controlled trial

Clinical Infectious Diseases

Volumn 64, Issue 3, 2017, Pages 265-271

  Hota, Susy S ^a,b   Sales, Valerie ^a,b,c   Tomlinson, George ^a,d   Salpeter, Mary Jane ^a   McGeer, Allison ^a,b   Coburn, Bryan ^a,b,e   Guttman, David S ^f,g   Low, Donald E ^a,b   Poutanen, Susan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MARKHAM STOUFFVILLE HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fecal transplantation; Intestinal microbiota; Randomized controlled trial; Recurrent Clostridium difficile infection; Vancomycin taper

Indexed keywords

ENEMA; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; AGED; ANOREXIA; ARTICLE; BLOATING; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIVERTICULITIS; END STAGE LIVER DISEASE; FATIGUE; FECAL MICROBIOTA TRANSPLANTATION; FECES INCONTINENCE; FECES MICROFLORA; FEMALE; FEVER; HUMAN; IMMUNOCOMPROMISED PATIENT; INTENTION TO TREAT ANALYSIS; MALE; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; RECURRENT INFECTION; RISK REDUCTION; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; ONTARIO; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; ONTARIO; RECURRENCE; VANCOMYCIN; YOUNG ADULT;

EID: 85016102187     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw731     Document Type: Article

References (33)

1. Loo VG, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2006; 354:2200-15.
2. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
3. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
4. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(suppl 2):1-26.
5. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-8.
6. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35:865-75.
7. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
8. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: A systematic review. J Clin Gastroenterol 2014; 48:693-702.
9. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: A systematic review. Ann Intern Med 2015; 162:630-8.
10. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
11. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41:835-43.
12. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58:1515-22.
13. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 2016; 315:142-9.
14. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med 2016; 165:609-16.
15. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med 2014; 34:787-98.
16. Bakken JS, Borody T, Brandt LJ, et al; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-9.
17. Moayyedi P, Marshall JK, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol 2014; 28:66-8.
18. Allen-Vercoe E, Reid G, Viner N, et al. A Canadian working group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 2012; 26:457-62.
19. US Food and Drug Administration. Draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Available at: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379. htm. Accessed 8 May 2016.
20. Health Canada. Guidance document: fecal microbiota therapy used in the treatment of Clostridium difficile infection not responsive to conventional therapies. Available at: http://www.hc-sc.gc.ca/dhp-mps/consultation/biolog/fecal-microbiota-bacterio-fecale-eng.php. Accessed 6 May 2016.
21. Gravel D, Miller M, Simor A, et al; Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009; 48:568-76.
22. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38:475-83.
23. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:580-5.
24. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscopy. Am J Gastroenterol 2000; 95:3284-3285.
25. Prayitno N, Akhavan P, Khan M, et al. Determination of the optimal storage duration and conditions for fecal transplantation (FTX) samples. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17-20 September 2011. Abstract K-203.
26. Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012; 6:1621-4.
27. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7:335-6.
28. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
29. Dmitrienko A, Wang MD. Bayesian predictive approach to interim monitoring in clinical trials. Stat Med 2006; 25:2178-95.
30. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://cran.r-project. org/bin/windows/base/old/3.2.1. Accessed 6 May 2016.
31. Abujamel T, Cadnum JL, Jury LA et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 2013; 8:e76269.
32. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867-8.
33. Jackson M, Olefson S, Machan JT, Kelly CR. A high rate of alternative diagnosis in patients referred for presumed Clostridium difficile infection. J Clin Gastroenterol 2015; 50:742-6.